Entrada Therapeutics, Inc. (TRDA): restructuring charge — Entrada Therapeutics restructures, reduces workforce 20% to focus on Duchenne MD candidates

Entrada Therapeutics, Inc.

Board approved strategic plan on April 29, 2025; workforce reduction of approximately 20% effective May 2.
Estimated $2 million in total charges (severance, healthcare) primarily in Q2 2025.
Company prioritizing DMD candidates ENTR-601-44, -45, -50, -51 and ocular programs.
Anticipates cost savings to extend cash runway into Q2 2027.
Workforce reduction substantially completed by end of Q2 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Entrada Therapeutics, Inc. announced a restructuring with charges of approximately $2 million affecting research areas (approximately 20%).

Type: restructuring
Charge: approximately $2 million
Affected area: research areas
Headcount: approximately 20%

Exact text from the filing

-45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-041204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.